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Deep sternal wound infections (DSWIs), although relatively rare, are associated with increased morbidity and mortality rates and decreased long-term life expectancy after cardiac surgery procedures. 1 Although the role of intravenous antibiotic prophylaxis and strict intraoperative glycemic control is beyond doubt, whether additional topically administered antibiotics may further reduce the incidence of DSWI remains a subject of fierce debate. A recent expert consensus review on the prevention and management of sternal wound infections (SWIs) 2 for the first time assigned a Class I Recommendation; Level of Evidence ¼ B for topical antibiotics to be applied to the cut edges of the sternum on opening and before closing all cardiac surgical procedures involving a sternotomy, as they been found to significantly reduce the incidence of SWIs. The aforementioned statement primarily was driven by several reports of excellent results achieved with implantable gentamicin-collagen sponges 3, 4 and vancomycin paste administered topically to the sternal edges.
5,E1,E2
One recent study, E3 in contrast to previous reports, demonstrated that vancomycin paste neither reduced the incidence of DSWI nor was its use was a negative predictor of DSWI in a multivariate analyses accounting for body mass index>30 kg/m 2 , New York Heart Association Class IV, or Society of Thoracic Surgeons DSWI Risk Index. Given the highest potential of this study to guide decision making because of the number of patients involved, we performed a systematic review and meta-analysis of studies assessing topical use of vancomycin in reducing the incidence of SWIs after cardiac surgery.
A meta-analysis was performed in accordance to Preferred Reporting Items for Systematic Reviews and meta-analyses statement.
E4
Major online databases (PubMed, MEDLINE, EMBASE, CENTRAL, Web of Science) as well as abstracts from major cardiothoracic surgery societies' meetings were screened for inclusion of relevant reports until December 31, 2016. Keywords used were ''vancom*cin; -paste, -gel, -ointment, -slurry''; ''topical*-, local*-vancom*cin''; ''vancom*cin AND stern*''; ''vancom*cin AND mediastin*.'' The search process was conducted by 2 reviewers (M.K. and G.M.R.); any divergences were resolved by a third reviewer (L.A.). Studies were considered eligible when comparing prophylactic topically administered vancomycin-based therapy versus no vancomycin/placebo in the setting of heart surgery performed via median sternotomy. Endpoints assessed were any SWIs, DSWIs, and superficial sternal wound infection (SSWIs). Risk ratio (RR) and 95% confidence intervals (CIs) served as primary statistics. Data were pooled in the meta-analysis via the DerSimonian and Laird random effects model. Data were analyzed at reported follow-ups. Publication bias was assessed by constructing a funnel plot in which logRR was plotted against standard error. P values were significant if less than or equal to .05. A Preferred Reporting Items for Systematic Reviews and meta-analyses flow diagram describing the study selection process along with reasons for exclusion is presented in Figure E1 . The initial search yielded 70 records; after exclusion of reports not pertinent to the design of the meta-analysis, E1,E2,E5,E6 4 studies 5,E3,E7,E8 (among them 1 randomized controlled trial E7 ) remained, which collectively enrolled 20,039 patients; 6843 received topically administered vancomycin intraoperatively, whereas 13,196 served as a control group. Baseline characteristics of included studies as well as endpoint definitions are listed in Table 1 .
Vancomycin dose varied across the studies and ranged from 250 mg E7 to 5 to 10 g. E3 In one study, vancomycin paste contained platelet-rich plasma E7 and in 2 thrombin as well. E7,E8 By visual inspection of funnel plot constructed for the endpoint SWI, there was no sign of publication bias for all but one study E3 ( Figure E2 ). Sources of potential bias are listed in Table E1 . Topically RCT, Randomized controlled trial; NA, not applicable; CABG, coronary artery bypass grafting; PRP, platelet-rich plasma; IV, intravenous; SWI, sternal wound infection; SSWI, superficial sternal wound infection; DSWI, deep sternal wound infection; NR, not reported; BIMA, bilateral internal mammary artery; BMI, body mass index; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association. *A logistic regression model was fit to estimate the likelihood of receiving the study intervention. Covariates included established risk factors identified by the Society of Thoracic Surgeons as well as other clinical and demographic factors; estimates from the resulting propensity model were then used to adjust the effect of the study intervention on DSWI in a logistic regression that used Firth's penalized maximum likelihood method. yA total of 444 propensitymatched pairs: The variables used for propensity score matching included ejection fraction, age, heart failure, peripheral vascular disease, endocarditis, diabetes, type of surgery, urgency of surgery, smoking, previous myocardial infarction, preoperative steroids, serum creatinine, weight, crossclamp time, and cardiopulmonary bypass time. zPatient characteristics that were statistically different. xAccording to Mangram and colleagues. administered vancomycin was associated with a 76% significant risk reduction of any SWI as compared with the control group: RR (95% CI): 0.24 (0.06-0.91) P ¼ .04; I 2 ¼ 70%; the corresponding event rates were 0.60% (41/ 6843) and 1.29% (171/13,196) in the vancomycin and control groups, respectively (Figure 1, A) . A sensitivity analysis performed by eliminating a single study, one at a time, and repeating the calculations, confirmed the direction and magnitude of the estimates ( Figure E3 ). Similar statistically significant risk reduction was demonstrated when analysis was restricted to DSWI: topical vancomycin reduced the risk of DSWI by 76%: RR (95% CI): 0.24 (0.06-0.99) P ¼ .05; I 2 ¼ 58% with corresponding event rates of 0.57% (39/6843) and 1.00% (132/13,196) for vancomycin and control groups, respectively (Figure 1, B) . Two studies only E3,E5 (N ¼ 5131) provided data on the incidence of SSWIs: although SSWIs occurred in 2 patients receiving topical vancomycin (0.12%) and 39 patients in the control group (1.11%), in random effects model, this difference was not significant: RR (95% CI): 0.20 (0.01-6.07) P ¼ .36; I 2 ¼ 78% (Figure 1, C) . In the largest study to date, Lander and colleagues E3 demonstrated that vancomycin paste did not reduce the incidence of DSWI after cardiac operations. In the current meta-analysis, this particular study was found to be the source of substantial heterogeneity in the analysis of SWIs, the reason being, apart from unbalanced baseline characteristics of the patients, certain methodologic flaws: (1) the study covers a 12-year period with indisputable changes involving perioperative antibiotics, glycemic control, and sternal closure techniques; (2) nonreporting of SSWIs; (3) exclusion, by design, of patients with infective endocarditis and receiving heart transplant, given their likelihood to gain most benefit from vancomycin paste; (4) exclusion of 9 patients who developed DSWI at 3 months after surgery and most importantly: and (5) indeed, vancomycin paste was used only in 25% of patients in the first 7 years (2321/9413 from the 2003 to 2010 time period) with 1.29% rate of DSWI (121 DSWI/9413 patients); in the second time period (2011) (2012) (2013) (2014) (2015) , vancomycin paste was used in 53% of patients (2676/5079 patients) with a rate of DSWI cut nearly ). This, in turn, suggests strong influence of factors other than topical vancomycin must have driven the results towards null.
In contrast, in a second largest (1075 vs 2190 patients) study group study by Lazar and colleagues, 5 topical vancomycin applied to the sternal edges, in conjunction with perioperative antibiotics and strict glycemic control, eliminated SSWIs (0% vs 1.6%; P <.0001), DSWIs (0% vs 0.7%; P ¼ .005), and any type of SWIs (0% vs 2.2%; P <.0001) in unselected consecutive cardiac surgical patients. Ease and applicability of vancomycin paste needs to be further mentioned; after mixing 2 g of vancomycin powder with a very small amount of saline (2 mL), it forms a wax much like bone wax that is applied to the cut edges of the sternal halves either (1) immediately after sternotomy E2 or (2) when the sternal wires are in place just before sternal approximation. 5 In conclusion, our results confirm the effectiveness of vancomycin in the discussed clinical scenario, thus supporting the recommendations of the recent expert consensus review on prevention and management of sternal wound infections. 2 Despite the fact that this meta-analysis is limited mainly to observational studies, it should help to guide decision-making regarding the intraoperative topical antibiotic prophylaxis of SWI, and in particular the vancomycin, until the results of upcoming research (eg, Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery [SWI Trial] NCT02374853) are available. 
